๐๐ผ๐ป๐ด ๐ง๐ฒ๐ฟ๐บ ยฎโข
Bajaj Auto 7400-8200 Expected level 9500 Support 6900
9700๐ฅLong term level hit
๐ฅ7โค1
Apollo Hospital Enterprise Ltd company details report
Apollo Hospital Enterprise Ltd (AHEL) is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. As on 31st March 2025, it has a total of 73 hospitals, of which 45 are owned including subsidiaries, JVs, and associates, 6 managed and 22 hospitals are towards cradles day surgeries (AHLL). The census bed capacity as on date is 10,187 beds with ~9,458 beds being operational. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under the name โApollo Pharmacyโ through a retail pharmacy chain of 6,626 outlets as on 31st March 2025. Apollo Healthcare and Lifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
Apollo Hospital Enterprise Ltd (AHEL) is one of the leading integrated healthcare service providers in Asia. It has a presence in hospital, pharmaceutical, primary care & diagnostic clinics. It also has telemedicine units across 10 countries, health insurance services, global projects consultancy, colleges of nursing and hospital management and a research foundation, epidemiological studies, stem cell & genetic research. As on 31st March 2025, it has a total of 73 hospitals, of which 45 are owned including subsidiaries, JVs, and associates, 6 managed and 22 hospitals are towards cradles day surgeries (AHLL). The census bed capacity as on date is 10,187 beds with ~9,458 beds being operational. Besides its hospital-based pharmacies, AHEL runs pharmacy operations under the name โApollo Pharmacyโ through a retail pharmacy chain of 6,626 outlets as on 31st March 2025. Apollo Healthcare and Lifestyle (AHLL) subsidiary covers the retail healthcare business of the Apollo group, comprising Apollo Clinics, Apollo Sugar, White Dental, Apollo Day Surgery centres and Apollo Cradle.
๐3๐1๐ฅ1
#SALES #GROWTH
FY25 has been a strong year for the company, continuing its momentum since the beginning of the financial year, followed by a double-digit growth across all three verticals. Sales grew by ~14% YoY to โน21,794 cr. Segment-wise, healthcare services grew by ~13% YoY (IP and OP volumes grew by ~7% and ~16% YoY); retail health & diagnostics by ~14% YoY, attributed to maturing network; digital health & pharmacy distribution by ~16% YoY, backed by growth in the omni channel pharmacy, followed by platform gross merchandise value (GMV) growth of ~8% YoY to ~โน3,007 cr. During the period, it added 607 pharmacy stores and closed 11 stores. With a net addition of 596 stores, the net count as on date stands at 6,626.
FY25 has been a strong year for the company, continuing its momentum since the beginning of the financial year, followed by a double-digit growth across all three verticals. Sales grew by ~14% YoY to โน21,794 cr. Segment-wise, healthcare services grew by ~13% YoY (IP and OP volumes grew by ~7% and ~16% YoY); retail health & diagnostics by ~14% YoY, attributed to maturing network; digital health & pharmacy distribution by ~16% YoY, backed by growth in the omni channel pharmacy, followed by platform gross merchandise value (GMV) growth of ~8% YoY to ~โน3,007 cr. During the period, it added 607 pharmacy stores and closed 11 stores. With a net addition of 596 stores, the net count as on date stands at 6,626.
โค2๐ซก2๐1๐ฅ1
#EBITDA #GROWTH
In FY25, EBITDA grew by ~26% YoY to โน3,022 cr, led by improved operating performance across hospitals and the HealthCo businesses. Segment-wise, EBITDA for hospitals stood at ~โน2,701 cr (v/s ~โน2,356 cr in FY24), diagnostics & retail health at ~โน154 cr (v/s ~โน117 cr in FY24). While the same for digital health & pharmacy distribution (excluding Apollo 24/7 operating costs) was โน754 cr (v/s ~โน626 cr in FY24). Apollo 24/7 operating cost stood at ~โน478 cr (including an ESOP non-cash charge of ~โน108 cr) v/s ~โน619 cr in FY24. Cost of raw material constituted ~13%, followed by other expenses ~22% (largely towards retainer fees to doctors and advertisements) and employee benefit expenses ~13%.
In FY25, EBITDA grew by ~26% YoY to โน3,022 cr, led by improved operating performance across hospitals and the HealthCo businesses. Segment-wise, EBITDA for hospitals stood at ~โน2,701 cr (v/s ~โน2,356 cr in FY24), diagnostics & retail health at ~โน154 cr (v/s ~โน117 cr in FY24). While the same for digital health & pharmacy distribution (excluding Apollo 24/7 operating costs) was โน754 cr (v/s ~โน626 cr in FY24). Apollo 24/7 operating cost stood at ~โน478 cr (including an ESOP non-cash charge of ~โน108 cr) v/s ~โน619 cr in FY24. Cost of raw material constituted ~13%, followed by other expenses ~22% (largely towards retainer fees to doctors and advertisements) and employee benefit expenses ~13%.
โก2๐2โค1
#PAT #GROWTH
In FY25, PAT grew by ~61% YoY to โน1,472 cr, driven by an improved topline and operating growth. Other income increased substantially by ~88% YoY to โน200 cr during the year. Segment-wise, PAT for hospitals was โน1,423 cr (v/s โน1,145 cr in FY24), diagnostics & retail health at negative โน27 cr (v/s negative โน51 cr in FY24). While the same for digital health & pharmacy distribution was โน47 cr (v/s negative โน196 cr in FY24), on account of optimization of cost and growth in operational revenue.
In FY25, PAT grew by ~61% YoY to โน1,472 cr, driven by an improved topline and operating growth. Other income increased substantially by ~88% YoY to โน200 cr during the year. Segment-wise, PAT for hospitals was โน1,423 cr (v/s โน1,145 cr in FY24), diagnostics & retail health at negative โน27 cr (v/s negative โน51 cr in FY24). While the same for digital health & pharmacy distribution was โน47 cr (v/s negative โน196 cr in FY24), on account of optimization of cost and growth in operational revenue.
๐1๐ฅ1๐1
#EBITDA #MARGIN
In FY25, EBITDA margin expanded by ~132 bps YoY to 13.9%. This was led by a decline in cost of materials consumed and other expenses as a percentage of sales. Segment-wise, EBITDA margins for the healthcare business was 24.2% (v/s 23.9% in FY24), diagnostics & retail health at 9.9% (v/s 8.5% in FY24). While the same for pharmacy distribution (excluding 24/7 operating cost) was 1.8%. The company has recruited additional doctors to boost volume and occupancy growth, restoring previous margin levels for the hospital business. Going forward, the focus will shift on cost efficiency, partially offset by the increased investment in Apollo 24/7.
In FY25, EBITDA margin expanded by ~132 bps YoY to 13.9%. This was led by a decline in cost of materials consumed and other expenses as a percentage of sales. Segment-wise, EBITDA margins for the healthcare business was 24.2% (v/s 23.9% in FY24), diagnostics & retail health at 9.9% (v/s 8.5% in FY24). While the same for pharmacy distribution (excluding 24/7 operating cost) was 1.8%. The company has recruited additional doctors to boost volume and occupancy growth, restoring previous margin levels for the hospital business. Going forward, the focus will shift on cost efficiency, partially offset by the increased investment in Apollo 24/7.
โก1โค1๐ฅ1๐ซก1
#ROCE
In FY25, ROCE for the company increased to 21.19%, aided by improving operating profit, despite increase in average capital employed. The company delivered a ROCE of 27.5% during FY25, with balanced ROCE across all geographies, including metros, tier 1 & tier 2 cities. Metro cities clocked in a ROCE of ~29% while that of non-metros was ~27%. Further, bed expansions and improvements in metrics across different regions helped in improving the operating profit and ROCE of the company.
In FY25, ROCE for the company increased to 21.19%, aided by improving operating profit, despite increase in average capital employed. The company delivered a ROCE of 27.5% during FY25, with balanced ROCE across all geographies, including metros, tier 1 & tier 2 cities. Metro cities clocked in a ROCE of ~29% while that of non-metros was ~27%. Further, bed expansions and improvements in metrics across different regions helped in improving the operating profit and ROCE of the company.
โค1๐1๐ฅ1๐ซก1
#ROE
In FY25, ROE increased to 20.51%, owing to rising net profit. The company has a focused presence towards different regions, offering services across hospitals, pharmacies, primary care & diagnostic clinics and several retail health chains. Strong patient volumes post-pandemic, improving GMV and cost efficiency drove the overall profit and improved the ROE. The company is foraying across new facilities which would help to widen its patient base. This will help in improving the profitability and maintaining strong return ratios of the company going ahead.
In FY25, ROE increased to 20.51%, owing to rising net profit. The company has a focused presence towards different regions, offering services across hospitals, pharmacies, primary care & diagnostic clinics and several retail health chains. Strong patient volumes post-pandemic, improving GMV and cost efficiency drove the overall profit and improved the ROE. The company is foraying across new facilities which would help to widen its patient base. This will help in improving the profitability and maintaining strong return ratios of the company going ahead.
๐ฅ1๐1๐ซก1
#SECTOR #POTENTIAL #HOSPITALS
โข Indian healthcare industry โ The industry is growing at a significant pace, owing to its strengthening coverage, services and increasing expenditure by the public and private sectors. Going forward, the industry is anticipated to grow, mainly driven by the increased government expenditure and initiatives to boost the healthcare sector, followed by better case mix, higher ARPOBs and bed additions. The sector is also witnessing significant private equity activity, with investments directed towards both multispecialty and single-specialty hospitals and clinics. โข Government Initiatives โ Various initiatives have been undertaken which seeks to comprehensively strengthen the healthcare system, right from primary to tertiary care, thereby providing healthcare assurance and increase the coverage of healthcare services. โข Health โข Urban/Rural โข Medical Insurance industry - The overall sector in India has undergone significant changes driven by regulatory reforms, technological advancements and increased public awareness. This further propels the demand for healthcare services as insurance policies partly cover health expenses, eventually reducing the healthcare cost burden and encouraging an individual to undergo treatment. shift - Existing hospital beds and hospitalization services have a high level of concentration in urban areas, which in turn impacts the accessibility and affordability of these services in rural areas. While in the public sector, ~61% of beds are present in urban areas, the proportion jumps to 80% in case of the private sector. On an aggregate level, 72% of total beds are in urban areas while only 28% are in rural areas. Expenditure - While the all-India average medical expenditure per hospitalization case in public hospitals is low, the same for private hospitals is high. Despite higher costs, mostly people depend on private hospitals for treatment as these largely meet service quality needs and demands.
โข Indian healthcare industry โ The industry is growing at a significant pace, owing to its strengthening coverage, services and increasing expenditure by the public and private sectors. Going forward, the industry is anticipated to grow, mainly driven by the increased government expenditure and initiatives to boost the healthcare sector, followed by better case mix, higher ARPOBs and bed additions. The sector is also witnessing significant private equity activity, with investments directed towards both multispecialty and single-specialty hospitals and clinics. โข Government Initiatives โ Various initiatives have been undertaken which seeks to comprehensively strengthen the healthcare system, right from primary to tertiary care, thereby providing healthcare assurance and increase the coverage of healthcare services. โข Health โข Urban/Rural โข Medical Insurance industry - The overall sector in India has undergone significant changes driven by regulatory reforms, technological advancements and increased public awareness. This further propels the demand for healthcare services as insurance policies partly cover health expenses, eventually reducing the healthcare cost burden and encouraging an individual to undergo treatment. shift - Existing hospital beds and hospitalization services have a high level of concentration in urban areas, which in turn impacts the accessibility and affordability of these services in rural areas. While in the public sector, ~61% of beds are present in urban areas, the proportion jumps to 80% in case of the private sector. On an aggregate level, 72% of total beds are in urban areas while only 28% are in rural areas. Expenditure - While the all-India average medical expenditure per hospitalization case in public hospitals is low, the same for private hospitals is high. Despite higher costs, mostly people depend on private hospitals for treatment as these largely meet service quality needs and demands.
โค2โก1๐ฅ1๐1
#FUTURE #OUTLOOK #HOSPITALS
โข With strong business fundamentals, a strategy to mitigate headwinds from the disruptions in inpatient flows from Bangladesh and multiple facilities scheduled for phased commissioning, they remain confident in sustaining the growth trajectory in FY26. โข The business shall continue to generate strong cash flows, supported by improved EBITDA margins, followed by cost reduction initiatives, that will help offset the potential losses. They estimate an overall margin improvement of around 140 bps, with 80 bps driven by cost efficiencies and the remaining 60 bps coming from the revenue growth through initiatives such as improving payer mix, case complexity, ARPOB and occupancy. โข The company is maintaining its strategic emphasis on volume growth while also enhancing its focus on high-end specialties such as cardiac sciences, oncology and neurosciences. This shift is expected to drive higher revenue intensity and improve the margin profile moving forward. โข They are on track to operationalize the previously announced facilities in Gurgaon, Pune, Kolkata and Hyderabad in the upcoming fiscal year. โข They have approved the brownfield expansion of 160 beds spread across the Jubilee Hills and Secunderabad facilities, which should become operational in the coming 3-4 years. โข The company has acquired a 200-bedded existing hospital in Sarjapur, expected to be integrated within the next two quarters, enhancing its care network and reach in South-East Bengaluru. Additionally, it has secured a 2.53-acre land parcel in Sarjapur for a 500-bed greenfield hospital, slated to become operational in the next 3-4 years. โข The company is looking at additional markets to support growth, including Iran, Iraq, Indonesia, Middle East, Africa and Sri Lanka. The regions have started witnessing patient footfalls
โข With strong business fundamentals, a strategy to mitigate headwinds from the disruptions in inpatient flows from Bangladesh and multiple facilities scheduled for phased commissioning, they remain confident in sustaining the growth trajectory in FY26. โข The business shall continue to generate strong cash flows, supported by improved EBITDA margins, followed by cost reduction initiatives, that will help offset the potential losses. They estimate an overall margin improvement of around 140 bps, with 80 bps driven by cost efficiencies and the remaining 60 bps coming from the revenue growth through initiatives such as improving payer mix, case complexity, ARPOB and occupancy. โข The company is maintaining its strategic emphasis on volume growth while also enhancing its focus on high-end specialties such as cardiac sciences, oncology and neurosciences. This shift is expected to drive higher revenue intensity and improve the margin profile moving forward. โข They are on track to operationalize the previously announced facilities in Gurgaon, Pune, Kolkata and Hyderabad in the upcoming fiscal year. โข They have approved the brownfield expansion of 160 beds spread across the Jubilee Hills and Secunderabad facilities, which should become operational in the coming 3-4 years. โข The company has acquired a 200-bedded existing hospital in Sarjapur, expected to be integrated within the next two quarters, enhancing its care network and reach in South-East Bengaluru. Additionally, it has secured a 2.53-acre land parcel in Sarjapur for a 500-bed greenfield hospital, slated to become operational in the next 3-4 years. โข The company is looking at additional markets to support growth, including Iran, Iraq, Indonesia, Middle East, Africa and Sri Lanka. The regions have started witnessing patient footfalls
โค4๐ฅ2๐1๐1
Apollo Hospital 6500-7000
Expected level 8800
Support 6000
Expected level 8800
Support 6000
๐ฅ5โค2
๐๐๐๐๐ฒ๐๐ฅ๐ข๐ง๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ ๐ข๐ง ๐๐ง๐๐ข๐.
โช๏ธIon Exchange (India) Ltd - Water Treatment
โช๏ธVa Tech Wabag Ltd - Water Treatment
โช๏ธJash Engineering Ltd - Water Treatment
โช๏ธFelix Industries Ltd - Water Treatment
โช๏ธGRP Ltd - Tyre Recycling
โช๏ธTinna Rubber & Infrastructure Ltd - Tyre Recycling
โช๏ธIndag Rubber Ltd - Tyre Recycling
โช๏ธElgi Rubber Company Ltd - Rubber Recycling
โช๏ธPondy Oxides & Chemicals Ltd - Lead Recycling
โช๏ธNILE Ltd - Lead Recycling
โช๏ธEco Recycling Ltd - E-waste Recycling
โช๏ธCerebra Integrated Technologies Ltd - E-waste Recycling
โช๏ธGravita India Ltd - Led, Aluminium & Plastic Recycling
โช๏ธNupur Recyclers Ltd - Metal Scrap Recycling
โช๏ธMSTC Ltd - Auto shredding, Metal Scrap and ship recycling
โช๏ธGanesha Ecosphere Ltd - Pet Waste Recycling
โช๏ธAntony Waste Handling Cell Ltd - Integrated waste management
โช๏ธIon Exchange (India) Ltd - Water Treatment
โช๏ธVa Tech Wabag Ltd - Water Treatment
โช๏ธJash Engineering Ltd - Water Treatment
โช๏ธFelix Industries Ltd - Water Treatment
โช๏ธGRP Ltd - Tyre Recycling
โช๏ธTinna Rubber & Infrastructure Ltd - Tyre Recycling
โช๏ธIndag Rubber Ltd - Tyre Recycling
โช๏ธElgi Rubber Company Ltd - Rubber Recycling
โช๏ธPondy Oxides & Chemicals Ltd - Lead Recycling
โช๏ธNILE Ltd - Lead Recycling
โช๏ธEco Recycling Ltd - E-waste Recycling
โช๏ธCerebra Integrated Technologies Ltd - E-waste Recycling
โช๏ธGravita India Ltd - Led, Aluminium & Plastic Recycling
โช๏ธNupur Recyclers Ltd - Metal Scrap Recycling
โช๏ธMSTC Ltd - Auto shredding, Metal Scrap and ship recycling
โช๏ธGanesha Ecosphere Ltd - Pet Waste Recycling
โช๏ธAntony Waste Handling Cell Ltd - Integrated waste management
โค6๐ฅ4๐2๐1